Interleukin-6 - Deficiency
Research News and Information

Sunday, November 22, 2009

The role of interleukin-6 in the formation of the coronary vasculature.

25 Aug 2009 The formation and the patterning of the coronary vasculature are critical to the development and pathology of the heart. Alterations in cytokine signaling and biomechanical load can alter the vascular distribution of the vessels within the heart. ... Read more...

Skin and peripheral lymph node invariant NKT cells are mainly retinoic acid receptor-related orphan receptor (gamma)t+ and respond preferentially under inflammatory conditions.

6 Jul 2009 Lymph nodes (LNs) have been long considered as comprising few invariant NKT (iNKT) cells, and these cells have not been studied extensively. In this study, we unravel the existence of stable rather than transitional LN-resident NK1.1(-) iNKT cell ... Read more...

Neutrophil-derived IL-6 limits alveolar barrier disruption in experimental ventilator-induced lung injury.

13 Jun 2009 IL-6 is a biological marker of ventilator-associated lung injury that may contribute to alveolar barrier dysfunction in acute respiratory distress syndrome. To determine whether IL-6 affects alveolar barrier disruption in a model of ... Read more...

Latest indexed articles for 'Interleukin-6 - Deficiency'

These are the very latest articles for this heading:

• The role of interleukin-6 in the formation of the coronary vasculature. 25 Aug 2009
• Skin and peripheral lymph node invariant NKT cells are mainly retinoic acid receptor-related orphan receptor (gamma)t+ and respond preferentially under inflammatory conditions. 6 Jul 2009
• Neutrophil-derived IL-6 limits alveolar barrier disruption in experimental ventilator-induced lung injury. 13 Jun 2009
• The T cell STAT signaling network is reprogrammed within hours of bacteremia via secondary signals. 13 Jun 2009
• Impaired hippocampus-dependent and -independent learning in IL-6 deficient mice. 6 Jun 2009
• Complement promotes the development of inflammatory T-helper 17 cells through synergistic interaction with Toll-like receptor signaling and interleukin-6 production. 31 May 2009
• The IL-6-deficient mouse exhibits impaired lymphocytic responses to a vaccine combining live Leishmania major and CpG oligodeoxynucleotides. 30 May 2009
• Downregulation of cilia-localized Il-6R alpha by 17beta-estradiol in mouse and human fallopian tubes. 4 May 2009
• Indirect recruitment of a CD40 signaling pathway in dendritic cells by B7-DC cross-linking antibody modulates T cell functions. 26 Apr 2009
• Interleukin-6 gene knockout influences energy balance regulating peptides in the hypothalamic paraventricular and supraoptic nuclei. 11 Apr 2009
• IL-6 and TNF-alpha synergistically inhibit allograft acceptance. 6 Apr 2009
• Mechanisms of the hepatic acute-phase response during bacterial pneumonia. 14 Mar 2009
• A pivotal role for CD40-mediated IL-6 production by dendritic cells during IL-17 induction in vivo. 27 Feb 2009
• IL-6 loss causes ventricular dysfunction, fibrosis, reduced capillary density, and dramatically alters the cell populations of the developing and adult heart. 18 Feb 2009
• Impact of interleukin-6 on hypoxia-induced pulmonary hypertension and lung inflammation in mice. 25 Jan 2009
• IL-6 and serum amyloid A synergy mediates angiotensin II-induced muscle wasting. 19 Jan 2009
• Therapeutic targeting of IL-6 trans signaling counteracts STAT3 control of experimental inflammatory arthritis. 30 Dec 2008
• Reversal of thymic stromal lymphopoietin-induced airway inflammation through inhibition of Th2 responses. 30 Oct 2008
• Localized inflammation in peripheral tissue signals the CNS for sickness response in the absence of interleukin-1 and cyclooxygenase-2 in the blood and brain. 29 Sep 2008
• Effect of IL-6 deficiency on susceptibility to HSV-1 respiratory infection and intrinsic macrophage antiviral resistance. 29 Sep 2008

See a longer list of these articles.

Technical information about 'Interleukin-6'

Definition: A cytokine that stimulates the growth and differentiation of B-LYMPHOCYTES and is also a growth factor for HYBRIDOMAS and plasmacytomas. It is produced by many different cells including T-LYMPHOCYTES; MONOCYTES; and FIBROBLASTS.

Registry Number: 0

Descriptor UI: D015850

Alternative terms: Interleukin-6; Interleukin 6; Plasmacytoma Growth Factor; Growth Factor, Plasmacytoma; B-Cell Differentiation Factor-2; B Cell Differentiation Factor 2; B-Cell Stimulatory Factor 2; B-Cell Stimulatory Factor-2; BSF-2; Differentiation Factor, B-Cell; Differentiation Factor, B Cell; Differentiation Factor-2, B-Cell; Differentiation Factor 2, B Cell; Hepatocyte-Stimulating Factor; Hepatocyte Stimulating Factor; Hybridoma Growth Factor; Growth Factor, Hybridoma; IFN-beta 2; IL-6; IL6; MGI-2; Myeloid Differentiation-Inducing Protein; Differentiation-Inducing Protein, Myeloid; Myeloid Differentiation Inducing Protein; B Cell Stimulatory Factor-2; B Cell Stimulatory Factor 2; B-Cell Differentiation Factor; B Cell Differentiation Factor;

Related Mesh Headings: Hybridomas; Plasmacytoma;

Allowable Qualifiers: administration & dosage; adverse effects; analogs & derivatives; analysis; antagonists & inhibitors; biosynthesis; blood; cerebrospinal fluid; chemical synthesis; classification; deficiency; diagnostic use; economics; genetics; history; immunology; isolation & purification; metabolism; pharmacokinetics; pharmacology; physiology; poisoning; radiation effects; secretion; standards; supply & distribution; therapeutic use; toxicity; urine; chemistry; contraindications; agonists;

Tree Number: D12.644.276.374.465.506; D12.776.467.374.465.506; D23.529.374.465.506;

History Note: 90

Technical Notes: DF: IL 6 or IL6